Injecting INT230-6 then immunochemo before surgery for early TNBC
Part of Cancer, Skin clinical trials.
This trial tests a two-step approach: first, an injection of the drug INT230-6 directly into the breast tumor, followed by a combination of immunotherapy and chemotherapy before surgery. The goal is to see if this sequence can shrink or eliminate the cancer more effectively, potentially allowing for a less extensive surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have early-stage triple-negative breast cancer (stages T1c to T4c, but not the inflammatory type) that has not spread to other organs.
- You must be 18 years or older and in generally good health (able to do most daily activities).
- The main tumor in your breast must be at least 1.5 cm and reachable with a needle for injection.
- You cannot have had any prior chemotherapy, radiation, or targeted therapy for this breast cancer.
- Your blood counts, liver, kidney, and heart function must be within a safe range (your doctor will check these).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding sintilimab (an immunotherapy) and bevacizumab (a drug that blocks blood supply to tumors) to standard chemotherapy before surgery can improve outcomes for women with stage II or III triple-negative breast cancer. It may help your immune system fight the cancer more effectively.
This trial tests whether adding an immunotherapy drug called toripalimab to standard chemotherapy, before surgery, can improve treatment for early triple-negative breast cancer. It compares two chemotherapy approaches—one with anthracyclines and one without—to see which works better when combined with toripalimab.
This trial tests whether adding an experimental drug called INBRX-106 to the standard immunotherapy (pembrolizumab) and chemotherapy before surgery can improve outcomes for patients with early-stage triple-negative breast cancer. The goal is to shrink the tumor and potentially reduce the risk of the cancer coming back.
This trial studies a new drug called QL1706 (an immunotherapy that helps your immune system fight cancer) combined with standard chemotherapy before surgery. The goal is to see if this combination can shrink or eliminate the tumor more effectively in early-stage triple-negative breast cancer, potentially improving your long-term outcome.
This trial tests a new combination of chemotherapy and immunotherapy that avoids a class of drugs called anthracyclines, which can be hard on the heart. The goal is to shrink tumors before surgery for people with triple-negative or low-hormone-receptor breast cancer.
This trial tests whether combining targeted radiation (SBRT) with immunotherapy (PD-1 inhibitor) and chemotherapy can improve outcomes for people with early-stage triple-negative breast cancer that has not spread far. It aims to find a more effective treatment option.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.